{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:07:08Z","timestamp":1792552028705,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":1293,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1093\/annonc\/mdw067","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T04:32:42Z","timestamp":1460003562000},"page":"812-818","source":"Crossref","is-referenced-by-count":257,"title":["A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)"],"prefix":"10.1016","volume":"27","author":[{"given":"H.","family":"Bonnefoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Grellety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"L'Haridon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dauba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Del Piano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Coussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Madranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.C.","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Proudhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"MacGrogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw067_bb0010","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","article-title":"Identification of molecular apocrine breast tumours by microarray analysis","volume":"24","author":"Farmer","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw067_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.onc.1209415","article-title":"An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen","volume":"25","author":"Doane AS","year":"2006","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw067_bb0020","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdw067_bb0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/onc.2011.301","article-title":"A refined molecular taxonomy of breast cancer","volume":"31","author":"Guedj","year":"2012","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw067_bb0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/modpathol.2011.54","article-title":"Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses\u2019 Health Study","volume":"24","author":"Collins","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdw067_bb0035","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr3421","article-title":"Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15","volume":"15","author":"Lehmann-Che","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdw067_bb0040","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw067_bb0045","series-title":"Results of a phase 2 study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer","author":"Traina","year":"2015"},{"key":"10.1093\/annonc\/mdw067_bb0050","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw067_bb0055","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw067_bb0060","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw067_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw067_bb0070","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1210\/me.2012-1107","article-title":"Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?","volume":"26","author":"Hickey","year":"2012","journal-title":"Mol Endocrinol"},{"key":"10.1093\/annonc\/mdw067_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/annonc\/mdv487","article-title":"Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer","volume":"27","author":"O'Shaughnessy","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw067_bb0080","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw067_bb0085","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw067_bb0090","series-title":"A novel biomarker to predict sensitivity to enzalutamide in triple-negative breast cancer","author":"Parker","year":"2015"},{"key":"10.1093\/annonc\/mdw067_bb0095","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1038\/emboj.2011.216","article-title":"Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1","volume":"30","author":"Robinson","year":"2011","journal-title":"Embo J"},{"key":"10.1093\/annonc\/mdw067_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccr.2011.05.026","article-title":"Targeting androgen receptor in estrogen receptor-negative breast cancer","volume":"20","author":"Ni","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdw067_bb0105","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13058-014-0406-x","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419374435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:09:43Z","timestamp":1624698583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419374435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0923753419374435"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw067","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}